Citadel Advisors’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-691,458
| Closed | -$1.02M | – | 14245 |
|
|
2022
Q2 | $1.02M | Sell |
691,458
-3,512,608
| -84% | -$2.58M | ﹤0.01% | 6984 |
|
|
2022
Q1 | $4.83M | Buy |
4,204,066
+3,427,731
| +442% | +$5.59M | ﹤0.01% | 4233 |
|
|
2021
Q4 | $1.94M | Buy |
776,335
+736,685
| +1,858% | +$2.89M | ﹤0.01% | 6310 |
|
|
2021
Q3 | $203K | Sell |
39,650
-27,199
| -41% | -$165K | ﹤0.01% | 11963 |
|
|
2021
Q2 | $556K | Sell |
66,849
-5,447
| -8% | -$45.9K | ﹤0.01% | 9832 |
|
|
2021
Q1 | $630K | Sell |
72,296
-731,872
| -91% | -$7.57M | ﹤0.01% | 9179 |
|
|
2020
Q4 | $8.73M | Buy |
804,168
+600,305
| +294% | +$7.41M | ﹤0.01% | 2828 |
|
|
2020
Q3 | $2.43M | Buy |
203,863
+76,526
| +60% | +$1.03M | ﹤0.01% | 4367 |
|
|
2020
Q2 | $2.04M | Buy |
127,337
+86,422
| +211% | +$1.51M | ﹤0.01% | 4541 |
|
|
2020
Q1 | $634K | Buy |
40,915
+16,520
| +68% | +$355K | ﹤0.01% | 6096 |
|
|
2019
Q4 | $600K | Sell |
24,395
-551,496
| -96% | -$8.19M | ﹤0.01% | 6518 |
|
|
2019
Q3 | $5.94M | Buy |
+575,891
| New | +$7.26M | ﹤0.01% | 2874 |
|
|
2019
Q1 | – | Sell |
-263,492
| Closed | -$2.95M | – | 10099 |
|
|
2018
Q4 | $1.62M | Buy |
263,492
+172,515
| +190% | +$1.32M | ﹤0.01% | 4492 |
|
|
2018
Q3 | $964K | Sell |
90,977
-719,142
| -89% | -$8.21M | ﹤0.01% | 5624 |
|
|
2018
Q2 | $11M | Buy |
810,119
+228,405
| +39% | +$3.55M | 0.01% | 1835 |
|
|
2018
Q1 | $10.3M | Buy |
581,714
+29,625
| +5% | +$500K | 0.01% | 1699 |
|
|
2017
Q4 | $6.93M | Buy |
552,089
+114,240
| +26% | +$1.66M | ﹤0.01% | 2104 |
|
|
2017
Q3 | $8.34M | Buy |
+437,849
| New | +$6.68M | 0.01% | 1770 |
|
|
2016
Q4 | – | Sell |
-29,349
| Closed | -$289K | – | 8052 |
|
|
2016
Q3 | $289K | Buy |
+29,349
| New | +$268K | ﹤0.01% | 5730 |
|
|
2016
Q1 | – | Sell |
-7,245
| Closed | -$116K | – | 8351 |
|
|
2015
Q4 | $116K | Sell |
7,245
-18,964
| -72% | -$281K | ﹤0.01% | 6528 |
|
|
2015
Q3 | $337K | Buy |
26,209
+16,970
| +184% | +$342K | ﹤0.01% | 5387 |
|
|
2015
Q2 | $222K | Sell |
9,239
-31,048
| -77% | -$597K | ﹤0.01% | 6183 |
|
|
2015
Q1 | $756K | Sell |
40,287
-10,688
| -21% | -$221K | ﹤0.01% | 4320 |
|
|
2014
Q4 | $962K | Sell |
50,975
-176,600
| -78% | -$4.13M | ﹤0.01% | 3817 |
|
|
2014
Q3 | $6.17M | Buy |
227,575
+211,993
| +1,360% | +$6.59M | 0.01% | 1804 |
|
|
2014
Q2 | $485K | Buy |
+15,582
| New | +$367K | ﹤0.01% | 4439 |
|
Other funds holding EPZM
Citadel Advisors's EPZM Position: Q3 2022 in Review
Citadel Advisors sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 691,458 shares — an estimated $1.02M sold.
Citadel Advisors first reported a position in EPZM in Q2 2014 and held it in 26 quarters. The position peaked at $11M in Q2 2018. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- Citadel Advisors reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- Citadel Advisors sold 691,458 Epizyme, Inc shares in Q3 2022, an estimated $1.02M.
- Citadel Advisors first reported a position in Epizyme, Inc in Q2 2014 and held it in 26 quarters.
- Citadel Advisors's Epizyme, Inc position peaked at $11M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.